Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CHIP-ping away at tau.

Dmitry Goryunov1, Ronald K H Liem

  • 1Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

The Journal of Clinical Investigation
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal neurofilament inclusions and segregations in dorsal root ganglia of a Charcot-Marie-Tooth type 2E mouse model.

PloS one·2017
Same author

Cytoskeletal Integrators: The Spectrin Superfamily.

Cold Spring Harbor perspectives in biology·2016
Same author

α-Internexin and Peripherin: Expression, Assembly, Functions, and Roles in Disease.

Methods in enzymology·2016
Same author

Preface.

Methods in enzymology·2016
Same author

Microtubule-Actin Cross-Linking Factor 1: Domains, Interaction Partners, and Tissue-Specific Functions.

Methods in enzymology·2016
Same author

Neurofilament light polypeptide gene N98S mutation in mice leads to neurofilament network abnormalities and a Charcot-Marie-Tooth Type 2E phenotype.

Human molecular genetics·2015
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
See all related articles

Carboxyl terminus of Hsp70-interacting protein (CHIP), working with Hsp90, aids in clearing abnormal tau protein (p-tau). Targeting Hsp90 may reduce p-tau buildup in neurodegenerative diseases like Alzheimer's.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Protein Degradation

Background:

  • Protein accumulation, particularly hyperphosphorylated tau (p-tau), is a key feature of neurodegenerative disorders such as Alzheimer's disease (AD).
  • Tau pathology is implicated in various neurological conditions, including Down's syndrome, supranuclear palsy, prion disease, and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
  • The clearance of abnormal tau species is crucial for neuronal health and involves chaperone-mediated processes.

Purpose of the Study:

  • To investigate the role of cochaperone proteins in the removal of hyperphosphorylated tau (p-tau).
  • To elucidate the specific involvement of carboxyl terminus of Hsp70-interacting protein (CHIP) and Hsp90 in p-tau degradation.
  • To explore the therapeutic potential of targeting these protein complexes for neurodegenerative diseases.

Related Experiment Videos

Main Methods:

  • Utilized biochemical assays to examine the interaction between CHIP, Hsp90, and p-tau.
  • Investigated the effect of CHIP and Hsp90 on the stability and degradation of p-tau species.
  • Assessed the impact of pharmacologic manipulation of Hsp90 on p-tau levels in cellular models.

Main Results:

  • Demonstrated that CHIP, in complex with Hsp90, actively participates in the removal of p-tau.
  • Showed that the CHIP-Hsp90 complex facilitates the degradation of abnormal tau protein.
  • Indicated that modulating Hsp90 function influences p-tau accumulation.

Conclusions:

  • CHIP and Hsp90 are critical components of the cellular machinery responsible for clearing p-tau.
  • Targeting the Hsp90 chaperone complex presents a potential therapeutic strategy to reduce p-tau accumulation in neurodegenerative diseases.
  • Pharmacologic interventions aimed at Hsp90 may offer a novel approach to treating conditions characterized by tau pathology.